Today: 19 May 2026
Quantum Stocks (IonQ, Rigetti, D-Wave, Quantum Computing Inc) Surge 700–6,000% – Bubble or Breakthrough? (Oct. 13, 2025)

Quantum Stocks (IonQ, Rigetti, D-Wave, Quantum Computing Inc) Surge 700–6,000% – Bubble or Breakthrough? (Oct. 13, 2025)

  • Quantum mania reaches fever pitch. Pure-play quantum companies IonQ (NYSE: IONQ), Rigetti (NASDAQ: RGTI), D-Wave (NYSE: QBTS) and Quantum Computing Inc (NASDAQ: QUBT) have soared several-fold in 2025, e.g. Rigetti is up ~4,000% year-over-year and IonQ ~700% . D-Wave and others have also run up strongly (D-Wave ~+2000% YOY ). By mid-October 2025, IonQ traded near ~$73–75 (an all-time high) , Rigetti around $47 , D-Wave about $33, and QUBT ~$24 (all vastly above their 2024 prices).
  • Weak fundamentals, big valuations. None of these pure-play quantum firms is yet profitable: annual revenues are in the single-digit millions ts2.tech ts2.tech while market caps run into the tens of billions. Barron’s warns that the quartet of Rigetti, IonQ, D-Wave and QUBT has risen nearly 4× on average in a year, “even though they generate relatively little revenue” tipranks.com ts2.tech. McKinsey’s 2035 forecast (quantum could grow from ~$1 B today to $72 B) suggests long-term promise, but experts caution current valuations outstrip fundamentals ts2.tech ts2.tech.
  • Recent corporate catalysts. In late Sept/early Oct, all three pure-plays hit new highs amid fresh announcements. Rigetti won ~$5.7 M in Novera orders and a $5.8 M U.S. Air Force quantum networking contract ts2.tech, while unveiling a 36-qubit “Cepheus” processor and partnerships (e.g. a $100M+ collaboration with Quanta, and an India R&D MOU) ts2.tech ts2.tech. IonQ inked deals and made bold acquisitions (e.g. a $1.08 B deal to buy Oxford Ionics and smaller buys of Vector Atomic, Lightsynq, Capella) ts2.tech ts2.tech. On Oct 7, IonQ also announced a strategic investment in Swedish trucking startup Einride (integrating quantum optimization), which sent IONQ shares up ~10% ts2.tech【52†[16]】. Quantum Computing Inc. (QUBT) surged after announcing a $750 M equity raise (oversubscribed private placement) and unveiling a photonic quantum encryption prototype ts2.tech ts2.tech. On the same day QUBT’s stock plunged 11% (on dilution fears) before rebounding with the sector’s rally ts2.tech.
  • Expert caution: “pure speculation.” The headlong rush has drawn warnings. CNBC’s Jim Cramer warned Rigetti is “pure speculation” – “I don’t know whether [it] is worth what it’s trading at” ts2.tech. A Barron’s column similarly cautioned that quantum names have surged ~4× despite “limited” commercial use, and that this “bubble may keep inflating until it is tested by fundamentals” tipranks.com ts2.tech. Morgan Stanley analyst Joseph Moore even projects potential plunges: he sees up to ~60% drops for both IonQ and Rigetti if sentiment reverses sharewise.com. Other strategists sound ambivalence – one Bank of America strategist hailed quantum as “the most important technological race of our generation,” yet many analysts still peg quantum stocks as high-risk “lottery ticket” plays ts2.tech.
  • Analyst ratings & price targets. Wall Street is divided. All covering analysts rate Rigetti a Buy or Strong Buy, but their price targets (~$20–24) lie well below the current $47 level ts2.tech, implying ~50% downside. (Exceptions: Benchmark recently raised RGTI to $50, B. Riley $35 ts2.tech.) IonQ’s consensus 12-month target (~$58) suggests downside from ~$75 ts2.tech, though Needham and B. Riley have targets of $80–$100 ts2.tech. TipRanks highlights other quantum plays: analysts see 20%+ upside in Quantum Computing Inc (QUBT, avg target $32 ≈ +64%) and even in diversified names with quantum exposure – Honeywell (its Quantinuum unit raised $600M, HON target +24%) and Microsoft (MSFT target +23%) tipranks.com tipranks.com. In sum, bulls tout huge growth potential (even Barron’s noted QUBT “could rise 86%” more ts2.tech), while bears point to sky-high P/S ratios and tiny sales (QUBT had just $61K revenue in Q2 against a multi-$B valuation ts2.tech).
  • Big-tech context & forecasts. Tech giants and governments are doubling down on quantum: IBM, Google (Alphabet), Microsoft, Intel and Amazon all pour billions into R&D. IBM’s stock itself has rallied to multi-year highs (~$280) after unveiling a quantum breakthrough and new AI deals ts2.tech. Major forecasts still see quantum as a long-term winner: McKinsey (among others) expects market size to grow from ~$1 B today to ~$72 B by 2035 ts2.tech ts2.tech (BCC Research even projects over $1 trillion in economic impact). But such projections assume quantum computing achieves true scale in the 2030s. For now the sector’s “boom” is fueled largely by speculative mania, as reflected in charts and valuations.

In short: The quantum wave shows no signs of cresting – stocks like IonQ, Rigetti and QUBT continue to race higher on every piece of news. Current share prices, however, embed aggressive future growth that isn’t yet realized. As one commentator put it, many investors are “buying a vision of the future” ts2.tech. The coming months will test whether these parabolic runs are the start of a historic tech breakout or the peak of a frothy bubble. (All data as of mid-October 2025.)

Sources: Recent Barron’s/TipRanks reports , TipRanks analyses , and TechStock² (TS2.tech) deep-dives on IonQ, Rigetti, QUBT and others . These include expert quotes, SEC filings and up-to-date stock statistics.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Q1 Earnings Review: Knowles Outshines Peers in Electronic Components Sector
    May 19, 2026, 6:20 AM EDT. Electronic components & manufacturing sector posted strong Q1 results, with revenues beating analysts' consensus by 3.8% and share prices rising 11% on average. Knowles (NYSE:KN) led within the group, reporting $153.1 million in revenues, up 15.8% year-on-year, surpassing expectations by 3.9%. CEO Jeffrey Niew highlighted solid revenue and earnings per share (EPS) performance. Knowles shares gained 13.4% post-earnings, trading at $35.45. TTM Technologies (NASDAQ:TTMI) posted the best overall quarter with revenues up 30.4%, beating estimates by 6.9%, and shares climbing 16% to $159.48. Sector growth prospects include expanding demand in automotive, healthcare, aerospace, and computing. Risks remain from geopolitical tensions and environmental regulations. Analysts remain cautious but optimistic on the sector outlook.

Latest articles

Hesai Up Premarket After Mercedes Lidar Win, Q1 Profit

Hesai Up Premarket After Mercedes Lidar Win, Q1 Profit

19 May 2026
Hesai Group shares rose 2.68% to $22.60 in U.S. premarket trading after reporting a first-quarter profit and confirming it will supply lidar sensors for Mercedes-Benz Level 3 autonomous models. The company shipped 471,723 lidar units, up 140.9% year-on-year, and posted revenue of RMB680.6 million ($98.7 million). Net income reached RMB18.3 million, reversing a loss from a year earlier.
Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

19 May 2026
Virax Biolabs shares surged 53.1% Monday to $0.2350 and climbed another 17.1% in early Tuesday premarket trading, hitting $0.2751. The rally followed a paid RedChip TV appearance and a May 15 ownership filing showing Armistice Capital with a 4.99% stake. No new clinical or product updates were posted. Trading volume Monday reached about 765.2 million shares.
Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

19 May 2026
Amesite Inc. shares surged 218% to $2.50 in premarket trading after announcing its largest NurseMagic deployment with a 2,700-patient home-care client. The company disclosed $83,332 in quarterly revenue and a $678,061 net loss, with cash at $740,711 before a $2.2 million April financing. Amesite did not reveal the new contract’s value or customer name. Its latest filing cited “substantial doubt” about ongoing operations.

Popular

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

19 May 2026
Sunshine Biopharma shares surged as much as 516% before settling up 78% at $0.51 in heavy after-hours Nasdaq trading Monday, following a $6 million public offering priced at $0.50 per unit. More than 436 million shares changed hands, far exceeding the company’s 5 million shares outstanding. The deal includes 12 million units with warrants, raising dilution concerns. Closing is expected around May 19.
Verizon (VZ) Stock’s Wild Ride: New CEO & $20B Deal – Analysts Are Buzzing
Previous Story

Verizon (VZ) Stock’s Wild Ride: New CEO & $20B Deal – Analysts Are Buzzing

BYD’s European EV Invasion – Boom in Sales but Stock Takes a Hit
Next Story

BYD’s European EV Invasion – Boom in Sales but Stock Takes a Hit

Go toTop